Login to Your Account

Avigen Gains Neurology Drug In Agreement With Sanochemia

By Aaron Lorenzo

Wednesday, January 18, 2006
Avigen Inc. is expanding its portfolio by way of an in-licensing deal that brings in tolperisone (AV650), a small molecule for disabling neuromuscular conditions, further distancing itself from its past as a gene therapy firm. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription